King, I hope you're right, But IMHO this stock is so manipulated its not funny. Somebody knows something here and has insider information, They have no fear whatsoever in shorting this stock, They know they have all the time they need to cover, That is a big advantage IMO They know something that we dont. This Company dosent give a rats behind about us shareholders, The insiders here are IMO lining their own pockets, I may be wrong but I don't think so
Still Noooo news, Still Noooo company update, FRUSTRATION DOSENT COME CLOSE TO DESCRIBING THIS POS. ZZZZZZZZ
If you wait long enough , you may anything with this stock.
And that means you'll need an 82 pct. Gain to break out even, not out of the question.
Here is the original PR. "BG Medicine Announces Research Agreement With Boston Scientific on Biomarkers Relevant to Congestive Heart Failure and Cardiac-Resynchronization Therapy
WALTHAM, Mass., March 30, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has entered into a research collaboration agreement with Boston Scientific Corporation, a leading medical device manufacturer, to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy (CRT) using patient data from the MADIT-CRT study. The collaboration is designed to focus on better understanding the important MADIT-CRT patient population and whether galectin-3 can help identify patients who would derive the most benefit from CRT. This collaboration also involves using BG Medicine's biomarker discovery capabilities to identify other biomarkers that correlate to CRT Treatment Response
Enrique. In general I tend to side with the company because in many cases they fail to mention the company's name. But in this case they do mention BG Medicine, So like you I am beside myself.- Determination of Biomarkers
Whole blood (EDTA) was shipped on the day of collection, at room temperature, to a core laboratory for plasma processing and storage at -80 C. Galectin-3 concentrations were determined from the banked specimens (thawed once) using a commercial enzyme-linked immunosorbent assay (BG Medicine, Waltham, MA). All laboratory personnel conducting measurements on specimens were blinded to any patient-level data. BNP measurements were performed for the full MADIT-CRT trial by a core laboratory using the ADVIA Centaur BNP Assay (Bayer Diagnostics, Tarrytown, NY).
Enrique, I may have posted this in the past, Why I posted it again is, It was published in the Journal Of Cardiac Failure today, I think if I had posted it before, It was in the form of an Abstract, Being picked up by this Journal is IMHO a big deal.
Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial - cardiac resynchronization therapy)
Journal of Cardiac Failure, 09/19/2014 Clinical Article
Stolen CM, et al. – The present study investigated the relationship between galectin–3 level and clinical outcomes in HF patients randomized to implantable cardioverter defibrillator (ICD–only) or cardiac resynchronization therapy (CRT–D).
Elevated galectin–3 was found to be an independent predictor of adverse HF outcome in patients with mildly symptomatic HF. A significant interaction of device randomization group with pre–implantation galectin–3 level was detected, with HF patients having the highest baseline galectin–3 levels deriving a disproportionately larger benefit from CRT–D therapy.
That I am, I believe that the Abbott deal is still in trouble, But I also believe that Galectin 3 in the end will be a BIG winner, And don't forget about CardioScore, Game not over yet
I'm looking for bargains, And IM GETTING THEM
Enrique, With respect, That is what medicare will reimburse, Not what companies like Lab Corp and Mayo Clinic change, If you look around you'll find prices are all over the place. From $200 to $500 for the test
This article tells me that these studys are using BG Medicine's Test as mentioned above as this is the only FDA Approved Galectin 3 test " (ELISA) has been approved by the US Food and Drug Administration (FDA) "
Just as galectin-3 has been shown to help detect early heart disease, it can also be utilized similarly in oncology. Because studies have shown that galectin-3 is overexpressed in several cancers, it could prove to be a useful diagnostic biomarker.1
We are beginning to see research addressing the potential role of galectin-3 monitoring as evidenced by a recent study that explored the use of galectin-3 testing as an adjunct to PSA testing in prostate cancer patients
In addition, research indicates that finding ways to block galectin-3 expression and/or activity could have an impact on disease outcomes and may contribute to overall treatment success.56 The galectin-3 ELISA assay is presently readily available to clinicians. The preliminary data support the incorporation of galectin-3 testing as a biomarker of cancer progression and as an aid to prognosis determination.
I think I may start buying back the shares I've sold after reading this whole article.
Galectin-3 is a β-galactoside-binding protein expressed by a variety of different types of human cells. Galectin-3 is found in the nuclease, cytoplasm, and cell surface and is also secreted into the circulation. Galectin-3 as a biomarker has been confirmed with connections to inflammation, fibrosis, and overall risk of mortality in the general population. A blood serum test has been approved as a biomarker in high-risk cardiovascular patients to monitor potential heart failure. Elevated levels of galectin-3 in the serum have been linked to the development of several different cancers as well as cancer metastasis. Preclinical cancer models have shown galectin-3 to be associated with tumor cell transformation, invasive behavior, and metastasis. This review summarizes the pathophysiological connection of galectin-3 and cancer presently in the literature, as well as the potential clinical value of galectin-3 as a prognostic oncology biomarker. Based on the preliminary data, the galectin-3 assay could become a contributing tool to help clinicians monitor treatment response and tumor progression, but further clinical studies evaluating galectin-3 levels and cancer progression are warranted.
Presently, galectin-3 testing by enzyme-linked immune-sorbent assay (ELISA) has been approved by the US Food and Drug Administration (FDA) as a serum biomarker in chronic heart failure patients. A study that followed 592 patients who had been hospitalized for heart failure found that galectin-3 levels were correlated with higher levels of inflammatory markers interleukin and C-reactive protein.19 Approval of galectin-3 as a biomarker by the FDA in this population is based on the confirmed connection to inflammation, fibrosis, and risk of mortality.20 Galectin-3 levels have also been shown to be a reliable predictor of all-cause mortality in humans.21 The relationships between galectin-3 levels, demographic characteristics, and risk factors of cardiovascular disease—ie, smoking, high blood pressure, serum lipid, body mass index—were highlighted in the landmark Prevention of Renal and Vascular ENd-stage Disease (PREVEND) study, which looked at 7968 subjects with a median follow-up of approximately 10 years and found that galectin-3 levels were independently predictive of all-cause mortality and correlated significantly with the known risk factors for cardiovascular disease
This process has nothing to do with BG Medicine, This process takes Galectins out of the blood , BG Medicine measures the Galectins in the blood. The only relationship Dr. Isaac Eliaz has with BGMD is he uses the Galectin 3 test in his work.
It's Getting Old
You are correct, I do not know, But what I do know is , If the company knows and its bad news, They are not going to tell you till the 3rd quarter results are out in Nov, They did the same thing with the first 510k filing in 2012 with Abbott, They are under no obligation to tell investors if the filing was turned down, they will tell you in the quarterly filing, But I do know something's not right here.